Primary role of type I interferons for the induction of functionally optimal antigen-specific CD8

Humans Interferon Type I / metabolism CD8-Positive T-Lymphocytes HIV Infections Interferons / metabolism Adjuvants, Immunologic
CD8(+) T cells HIV-1 HIV-2 STING Type I IFN

Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
May 2023
Historique:
received: 17 08 2022
revised: 20 03 2023
accepted: 23 03 2023
medline: 15 5 2023
pubmed: 15 4 2023
entrez: 14 4 2023
Statut: ppublish

Résumé

CD8 We developed an unbiased in vitro system to compare the de novo induction of antigen-specific CD8 HIV-2 primed functionally optimal antigen-specific CD8 HIV-2 primes CD8 This work was funded by INSERM, the Institut Curie, and the University of Bordeaux (Senior IdEx Chair) and by grants from Sidaction (17-1-AAE-11097, 17-1-FJC-11199, VIH2016126002, 20-2-AEQ-12822-2, and 22-2-AEQ-13411), the Agence Nationale de la Recherche sur le SIDA (ECTZ36691, ECTZ25472, ECTZ71745, and ECTZ118797), and the Fondation pour la Recherche Médicale (EQ U202103012774). D.A.P. was supported by a Wellcome Trust Senior Investigator Award (100326/Z/12/Z).

Sections du résumé

BACKGROUND BACKGROUND
CD8
METHODS METHODS
We developed an unbiased in vitro system to compare the de novo induction of antigen-specific CD8
FINDINGS RESULTS
HIV-2 primed functionally optimal antigen-specific CD8
INTERPRETATION CONCLUSIONS
HIV-2 primes CD8
FUNDING BACKGROUND
This work was funded by INSERM, the Institut Curie, and the University of Bordeaux (Senior IdEx Chair) and by grants from Sidaction (17-1-AAE-11097, 17-1-FJC-11199, VIH2016126002, 20-2-AEQ-12822-2, and 22-2-AEQ-13411), the Agence Nationale de la Recherche sur le SIDA (ECTZ36691, ECTZ25472, ECTZ71745, and ECTZ118797), and the Fondation pour la Recherche Médicale (EQ U202103012774). D.A.P. was supported by a Wellcome Trust Senior Investigator Award (100326/Z/12/Z).

Identifiants

DOI: 10.1016/j.ebiom.2023.104557 PMID: 37058769 PMC: PMC10130611
pubmed: 37058769
pii: S2352-3964(23)00122-6
doi: 10.1016/j.ebiom.2023.104557
pmc: PMC10130611
pii:
doi:

Substances chimiques

Interferon Type I 0
Interferons 9008-11-1
Adjuvants, Immunologic 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104557

Informations de copyright

Copyright © 2023. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of interests N.M. is a cofounder of Stimunity, a company that develops cGAMP-loaded VLPs. A.S.C has received honoraria from MSD and Gilead for lectures. F.P-C is an inventor on a patent application by the Institut Pasteur (Method for reprogramming CD8+ T cells to enhance their therapeutic potential and applications thereof, US 63/301,532).

Auteurs

Mariela P Cabral-Piccin (MP)

Université de Bordeaux, CNRS UMR 5164, INSERM ERL 1303, ImmunoConcEpT, 33000, Bordeaux, France; Sorbonne Université, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), 75013, Paris, France.

Laura Papagno (L)

Université de Bordeaux, CNRS UMR 5164, INSERM ERL 1303, ImmunoConcEpT, 33000, Bordeaux, France; Sorbonne Université, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), 75013, Paris, France.

Xavier Lahaye (X)

Institut Curie, INSERM U932, Immunity and Cancer Department, PSL Research University, 75005, Paris, France.

Federico Perdomo-Celis (F)

Institut Pasteur, Unité HIV Inflammation et Persistance, 75015, Paris, France.

Stevenn Volant (S)

Institut Pasteur, Hub Bioinformatique et Biostatistique, 75015, Paris, France.

Eoghann White (E)

Université de Bordeaux, CNRS UMR 5164, INSERM ERL 1303, ImmunoConcEpT, 33000, Bordeaux, France; Sorbonne Université, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), 75013, Paris, France.

Valérie Monceaux (V)

Institut Pasteur, Unité HIV Inflammation et Persistance, 75015, Paris, France.

Sian Llewellyn-Lacey (S)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, CF14 4XN, UK.

Rémi Fromentin (R)

Centre de Recherche du CHUM and Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, QC H2X 0A9, Canada.

David A Price (DA)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, CF14 4XN, UK; Systems Immunity Research Institute, Cardiff University School of Medicine, Cardiff, CF14 4XN, UK.

Nicolas Chomont (N)

Centre de Recherche du CHUM and Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, QC H2X 0A9, Canada.

Nicolas Manel (N)

Institut Curie, INSERM U932, Immunity and Cancer Department, PSL Research University, 75005, Paris, France. Electronic address: nicolas.manel@curie.fr.

Asier Saez-Cirion (A)

Institut Pasteur, Unité HIV Inflammation et Persistance, 75015, Paris, France; Institut Pasteur, Université Paris Cité, Viral Reservoirs and Immune Control Unit, 75015, Paris, France. Electronic address: asier.saez-cirion@pasteur.fr.

Victor Appay (V)

Université de Bordeaux, CNRS UMR 5164, INSERM ERL 1303, ImmunoConcEpT, 33000, Bordeaux, France; Sorbonne Université, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), 75013, Paris, France; International Research Center of Medical Sciences, Kumamoto University, Kumamoto, 860-0811, Japan. Electronic address: victor.appay@immuconcept.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Primary role of type I interferons for the...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interférons › Interféron de type I › Primary role of type I interferons for the...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Primary role of type I interferons for the...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Primary role of type I interferons for the...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interférons › Primary role of type I interferons for the...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Adjuvants immunologiques › Primary role of type I interferons for the...